帕利珠单抗在免疫抑制动物模型中对抑制呼吸道合胞病毒非常有效。
Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
作者信息
Ottolini M G, Curtis S R, Mathews A, Ottolini S R, Prince G A
机构信息
Department of Pediatrics, F Edward Hébert School of Medicine, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799, USA.
出版信息
Bone Marrow Transplant. 2002 Jan;29(2):117-20. doi: 10.1038/sj.bmt.1703326.
Respiratory syncytial virus (RSV) is widely recognized as a leading cause of pneumonia, with substantial mortality, in bone marrow transplant recipients. We tested the efficacy of a systemic monoclonal antibody (MAB) preparation possessing a high titer of anti-RSV neutralizing antibody, palivizumab (Synagis) for prophylaxis and therapy of RSV infection in cytoxan (CY) immunosuppressed cotton rats, a model in which the efficacy of a polyclonal anti-RSV product (Respigam) has been demonstrated. Both prophylaxis and therapy with this MAB were highly effective in reducing pulmonary viral replication. However, multiple sequential therapeutic doses of MAB were necessary to control rebound viral replication in continually suppressed animals.
呼吸道合胞病毒（RSV）被广泛认为是骨髓移植受者肺炎的主要病因，具有很高的死亡率。我们测试了一种具有高滴度抗RSV中和抗体的全身性单克隆抗体（MAB）制剂——帕利珠单抗（Synagis），用于在环磷酰胺（CY）免疫抑制的棉鼠中预防和治疗RSV感染，此前已证明一种多克隆抗RSV产品（Respigam）在该模型中有效。这种MAB的预防和治疗在减少肺部病毒复制方面都非常有效。然而，对于持续免疫抑制的动物，需要多次连续给予治疗剂量的MAB来控制病毒复制的反弹。
Zotero 插件